2,3-diamino-2-methylbutane | 214559-09-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2,3-diamino-2-methylbutane
• 英文别名: 1,1,2-trimethyl-ethanediyldiamine；1,1,2-Trimethyl-aethandiyldiamin；N,N'-trimethylethylene diamine；dimethyl-1,2-propanediamine；trimethylethylenediamine；2-Methylbutane-2,3-diamine
• CAS: 214559-09-8
• 化学式: C₅H₁₄N₂
• mdl: MFCD16547818
• 分子量: 102.18
• InChiKey: MIKNSPXOIZYKIT-UHFFFAOYSA-N

物化性质

• 沸点：
  139.8±8.0 °C(Predicted)
• 密度：
  0.859±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,3-diamino-2-methylbutane 生成 N,N'-(trimethyl-ethanediyl)-bis-toluene-4-sulfonamide
  参考文献：
  名称：

  ON 1,2 AND 1,4 ADDITION¹. III. NITROGEN TRIOXIDE AND TRIMETHYLETHYLENE

  摘要：

  DOI：

  10.1021/jo01214a011
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 sodium amalgam 、 乙醇 作用下， 生成 2,3-diamino-2-methylbutane
  参考文献：
  名称：

  Steric Effects and the Stability of Complex Compounds. IV. The Chelating Tendencies of C-Substituted Ethylenediamines with Copper(II) and Nickel(II) Ions^1,2

  摘要：

  DOI：

  10.1021/ja01633a002
• 作为试剂：
  描述：

  叔-丁基N-(5-甲基-3-吡啶基)氨基甲酸酯 在 正丁基锂 、 2,3-diamino-2-methylbutane 、 碘 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以14%的产率得到(4-iodo-5-methyl-pyridin-3-yl)-carbamic acid tert-butyl ester
  参考文献：
  名称：

  [EN] NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS
  [FR] NOUVELLES AMIDINES DE THIOPHENE, COMPOSITIONS DE CES AMIDINES ET PROCEDE POUR TRAITER DES MALADIES ET DES ETATS MEDIES PAR LE COMPLEMENT

  摘要：

  揭示了一种治疗急性或慢性疾病症状的方法，该方法通过补体级联的经典途径介导，包括向需要此类治疗的哺乳动物施用化合物I的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中规范中定义了R1、R2、R3、R4和R7，Z为SO或SO2，Ar为本规范中定义的芳香族或杂环芳基。

  公开号：

  WO2003099805A1

文献信息

• Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20040009995A1

  公开（公告）日：2004-01-15

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R 1 , R 2 , R 3 , R 4 and R 7 are defined in the specification, Z is SO or SO 2 , and Ar is an aromatic or heteroaromatic group as defined herein.

  揭示了一种治疗急性或慢性疾病症状的方法，该方法通过补体级联的经典途径介导，包括向需要此类治疗的哺乳动物施用公式I的化合物的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中在规范中定义了R1、R2、R3、R4和R7，Z为SO或SO2，Ar为本文中定义的芳香族或杂环芳基。
• Intermediates and processes for preparing 4-substituted 2-5(H)-furanones
  申请人：Allergan, Inc.

  公开号：US05082954A1

  公开（公告）日：1992-01-21

  Anti-inflammatory 4-substituted 2-furanones are made from intermediates having the formulas: ##STR1## in which R.sub.1, R.sub.2 and R.sub.3 independently are n-alkyl of 1 to 6 carbons, or branched chain alkyl of 1 to 6 carbons; X is H, OH, NH.sub.2, I or Br; R.sub.4 is H, alkyl of 1-20 carbons, phenyl[C.sub.1 -C.sub.20 alkyl], naphthyl[C.sub.1 -C.sub.20 alkyl], CH.sub.2 OH, CH.sub.2 NH.sub.2, CH.sub.2 CH.sub.2 OH, CH.sub.2 --CHO, CH.sub.2 --COOH or CH.sub.2 --COOR.sub.5, and R.sub.5 is alkyl of 1 to 6 carbons, with the proviso that when X is hydrogen then R.sub.4 is selected from the group consisting of CH.sub.2 OH, CH.sub.2 NH.sub.2, CH.sub.2 CH.sub.2 OH, CH.sub.2 --CHO, or CH.sub.2 --COOR.sub.5 ; ##STR2## in which R.sub.1, R.sub.2 and R.sub.3 independently are n-alkyl of 1 to 6 carbons, or branched chain alkyl or 1 to 6 carbons, and R.sub.5 is alkyl or 1 to 6 carbons; ##STR3## in which R.sub.1, R.sub.2 and R.sub.3 independently are n-alkyl of 1 to 6 carbons, or branched chain alkyl of 1 to 6 carbons, and R.sub.6 is phenyl, or alkyl of 1 to 6 carbons, and ##STR4## in which R.sub.1, R.sub.2 and R.sub.3 independently are n-alkyl of 1 to 6 carbons, or branched chain alkyl of 1 to 6 carbons.

  抗炎症的4-取代的2-呋喃酮是由具有以下结构的中间体制备的：##STR1## 其中R.sub.1，R.sub.2和R.sub.3独立地是1到6个碳原子的n-烷基，或者1到6个碳原子的支链烷基；X是H，OH，NH.sub.2，I或Br；R.sub.4是H，1-20个碳原子的烷基，苯基[C.sub.1-C.sub.20烷基]，萘基[C.sub.1-C.sub.20烷基]，CH.sub.2 OH，CH.sub.2 NH.sub.2，CH.sub.2 CH.sub.2 OH，CH.sub.2 --CHO，CH.sub.2 --COOH或CH.sub.2 --COOR.sub.5，而R.sub.5是1到6个碳原子的烷基，但当X为氢时，R.sub.4从CH.sub.2 OH，CH.sub.2 NH.sub.2，CH.sub.2 CH.sub.2 OH，CH.sub.2 --CHO或CH.sub.2 --COOR.sub.5的组中选择；##STR2## 其中R.sub.1，R.sub.2和R.sub.3独立地是1到6个碳原子的n-烷基，或者1到6个碳原子的支链烷基，而R.sub.5是1到6个碳原子的烷基；##STR3## 其中R.sub.1，R.sub.2和R.sub.3独立地是1到6个碳原子的n-烷基，或者1到6个碳原子的支链烷基，而R.sub.6是苯基，或者1到6个碳原子的烷基，以及##STR4## 其中R.sub.1，R.sub.2和R.sub.3独立地是1到6个碳原子的n-烷基，或者1到6个碳原子的支链烷基。
• Pharmaceutical compositions and method for administering 3 and
  申请人：Allergan, Inc.

  公开号：US05268387A1

  公开（公告）日：1993-12-07

  3 and 4-substituted 2(5H)-furanone compounds influence the balance between bone production and bone resorption in mammals, including humans. The active compounds are administered to mammals, including humans, in an effective dose which ranges between 0.05 to 100 mg per kilogram, body weight, per day, for the purpose of influencing the balance between bone production and bone resorption, and particularly for treating osteoporosis.

  3和4-取代的2(5H)-呋喃酮化合物影响哺乳动物，包括人类的骨生成和骨吸收之间的平衡。这些活性化合物以有效剂量（每公斤体重范围在0.05至100毫克之间）被用于哺乳动物，包括人类，旨在影响骨生成和骨吸收之间的平衡，特别用于治疗骨质疏松症。
• Phenyl or heteroaryl and tetrahydronaphthyl substituted diene compounds
  申请人：Allergan, Inc.

  公开号：US05475022A1

  公开（公告）日：1995-12-12

  Compounds of Formula 1 ##STR1## wherein m is 1-4; R.sub.1 --R.sub.4 independently are hydrogen, lower alkyl of 1 to 6 carbons, Cl, Br, or I; R.sub.5 is hydrogen, lower alkyl of 1 to 6 carbons, Cl, Br, I, lower alkoxy or lower thioalkoxy of 1-6 carbons; R.sub.6 is hydrogen, lower alkyl, Cl, Br, I, OR.sub.11, SR.sub.11, OCOR.sub.11, SCOR.sub.11, NH2, NHR.sub.11, N(R.sub.11).sub.2, NHCOR.sub.11 OR NR.sub.11 --COR.sub.11 ; R.sub.20 is independently hydrogen or lower alkyl; Y is an aromatic group such as phenyl or naphthyl, or a heteroaryl group selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl and oxazolyl; A is (CH.sub.2).sub.n where n is 0-5, lower branched chain alkyl having 3-6 carbons, cycloalkyl having 3-6 carbons, alkenyl having 2-6 carbons and 1 or 2 double bonds, alkynyl having 2-6 carbons and 1 or 2 triple bonds; B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COOR.sub.8, CONR.sub.9 R.sub.10, --CH.sub.2 OH, CH.sub.2 OR.sub.11, CH.sub.2 OCOR.sub.11, CHO, CH(OR.sub.12).sub.2, CHOR.sub.13 O, --COR.sub.7, CR.sub.7 (OR.sub.12).sub.2, or CR.sub.7 OR.sub.13 O, where R.sub.7 is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons, R.sub.8 is an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5 to 10 carbons, or R.sub.8 is phenyl or lower alkylphenyl, R.sub.9 and R.sub.10 independently are hydrogen, an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5-10 carbons, or phenyl or lower aklylphenyl, R.sub.11 is lower alkyl, phenyl or lower alkylphenyl, R.sub.12 is lower alkyl, and R.sub.13 is divalent alkyl radical of 2-5 carbons, have retinoid like biological activity. In the compounds of the invention the A-B and the butadiene groups are attached to adjacent aromatic carbons of the Y moiety.

  式1的化合物##STR1##其中m为1-4；R.sub.1至R.sub.4独立地为氢、1至6个碳原子的低碳基、氯、溴或碘；R.sub.5为氢、1至6个碳原子的低碳基、氯、溴、碘、1-6个碳原子的低烷氧基或低硫代烷氧基；R.sub.6为氢、低碳基、氯、溴、碘、OR.sub.11、SR.sub.11、OCOR.sub.11、SCOR.sub.11、NH2、NHR.sub.11、N(R.sub.11).sub.2、NHCOR.sub.11或NR.sub.11 --COR.sub.11；R.sub.20独立地为氢或低碳基；Y为芳香基，如苯基或萘基，或从吡啶基、噻吩基、呋喃基、吡啶啉基、嘧啶基、吡嗪基、噻唑基和噁唑基组成的杂环基；A为(CH.sub.2).sub.n，其中n为0-5，具有3-6个碳原子的低支链烷基，具有3-6个碳原子的环烷基，具有2-6个碳原子和1或2个双键的烯基，具有2-6个碳原子和1或2个三键的炔基；B为氢、COOH或其药用可接受盐，COOR.sub.8、CONR.sub.9 R.sub.10、--CH.sub.2 OH、CH.sub.2 OR.sub.11、CH.sub.2 OCOR.sub.11、CHO、CH(OR.sub.12).sub.2、CHOR.sub.13 O、--COR.sub.7、CR.sub.7 (OR.sub.12).sub.2或CR.sub.7 OR.sub.13 O，其中R.sub.7为含有1至5个碳原子的烷基、环烷基或烯基，R.sub.8为1至10个碳原子的烷基，或5至10个碳原子的环烷基，或R.sub.8为苯基或低烷基苯基，R.sub.9和R.sub.10独立地为氢、1至10个碳原子的烷基，或5-10个碳原子的环烷基，或苯基或低烷基苯基，R.sub.11为低碳基、苯基或低烷基苯基，R.sub.12为低碳基，R.sub.13为2-5个碳原子的二价烷基基团，具有类似视黄醇的生物活性。在本发明的化合物中，A-B和丁二烯基团连接到Y基团的相邻芳香碳上。
• Tricyclic benzoylcyclohexanedione derivatives
  申请人：BASF Aktiengesellschaft

  公开号：US06583089B1

  公开（公告）日：2003-06-24

  Tricyclic benzoylcyclohexanedione derivatives of the formula I where X, Y, R1, R2, R3, R4, R5, R9, and m are defined herein, and their agriculturally useful salts. Process for preparing the tricyclic benzoylcyclohexanedione derivatives; compositions comprising them and the use of these derivatives or of the compositions comprising them for controlling undesirable plants are described.

  三环苯甲酰环己酮二酮衍生物的化学式为I，其中X、Y、R1、R2、R3、R4、R5、R9和m在此定义，并其在农业上有用的盐。描述了制备三环苯甲酰环己酮二酮衍生物的方法；包含它们的组合物以及利用这些衍生物或包含它们的组合物来控制不良植物的用途。